Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis

This study is currently recruiting participants.
Verified June 2012 by Universitaire Ziekenhuizen Leuven
Sponsor:
Information provided by (Responsible Party):
Edith Vermeulen, Universitaire Ziekenhuizen Leuven
ClinicalTrials.gov Identifier:
NCT01247142
First received: November 23, 2010
Last updated: June 4, 2012
Last verified: June 2012

November 23, 2010
June 4, 2012
January 2011
June 2013   (final data collection date for primary outcome measure)
The identification of biomarkers for invasive pulmonary aspergillosis (IPA) in exhaled breath condensate (EBC) [ Time Frame: 15 months ] [ Designated as safety issue: No ]
The identification of biomarkers for IPA in EBC [ Time Frame: 15 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01247142 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis
Not Provided

The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.

Invasive pulmonary aspergillosis (IPA) is a life-threatening infection in immunocompromised patients. The poor prognosis of the disease is partly attributed to difficulties encountered with the diagnosis of this infection. Invasive sampling procedures are often precluded in these patients. In addition, conventional diagnostic techniques lack sensitivity. Recently there has been increasing interest in the investigation of the lungs by noninvasive means including measurement of biomarkers in exhaled breath (e.g. NO) and those found in the cooled and condensed exhalate,termed EBC. It has been demonstrated that a measurable fraction of the EBC in healthy subjects is derived from aerosolized airway lining fluid. The presence of biomarkers for IPA will be investigated in EBC of patients with IPA, compared to controls.

Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

exhaled breath condensate

Probability Sample

Hospitalized adult patients of the department of Hematology, University Hospital, Leuven, Belgium

Invasive Pulmonary Aspergillosis
Not Provided
  • Invasive pulmonary aspergillosis (IPA)
    Patients with proven or probable invasive pulmonary aspergillosis (IPA) (EORTC/MSG criteria)
  • Controls
    Patients without signs of infection.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
20
August 2013
June 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • hospitalisation in the hematology department
  • age > 16 years
  • informed consent
  • proven or probable IPA (EORTC/ MSG criteria)
  • galactomannan positivity in BAL or serum

Exclusion Criteria:

  • age < 16 years
Both
16 Years and older
Yes
Contact: Edith Vermeulen +32 16 34 79 25 edith.vermeulen@uzleuven.be
Belgium
 
NCT01247142
S52756
No
Edith Vermeulen, Universitaire Ziekenhuizen Leuven
Universitaire Ziekenhuizen Leuven
Not Provided
Not Provided
Universitaire Ziekenhuizen Leuven
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP